News / Insights
The Future of Cell & Gene Therapy Logistics
Cell and gene therapies are changing the way some of the world's most complex diseases are treated. They are also creating an entirely new set of challenges for pharmaceutical supply chains.
Unlike conventional medicines, many advanced therapies involve highly sensitive biological materials with strict temperature requirements, limited stability windows and, in some cases, a direct connection to an individual patient.
For logistics providers, there is very little margin for error.
As personalised medicine continues to develop, the ability to move these materials safely, quickly and under tightly controlled conditions will become increasingly important.
Precision Is Becoming More Important
Cell and gene therapy logistics is not simply about moving a temperature-controlled package from one location to another.
Every stage of the journey needs to be coordinated around the requirements of the material.
This can include collection from a clinical site, transport to a manufacturing facility, movement between laboratories and the final delivery of a therapy back to the treatment centre.
Timing, temperature and traceability need to remain aligned throughout that process.
Temperature Control Is Critical
Advanced therapies can require highly specific storage and transport conditions.
Depending on the material, this may involve refrigerated, frozen or cryogenic transportation.
The packaging solution therefore needs to be selected according to the required temperature range, expected transit duration, route and potential risks associated with the journey.
Continuous temperature monitoring can provide additional visibility and help demonstrate that required conditions have been maintained during transportation.
Chain of Custody Matters
For patient-specific therapies, maintaining a clear chain of custody is particularly important.
The logistics process must provide visibility over where the material is, who has handled it and how it has moved through the supply chain.
This becomes even more important when a therapy crosses international borders or moves between multiple facilities.
Accurate documentation and clearly defined handovers help protect both the material and the integrity of the overall process.
Planning for the Unexpected
A delayed flight or customs hold can have significant consequences when dealing with time-sensitive biological materials.
Contingency planning should therefore be built into the logistics strategy from the beginning.
Alternative routes, carrier options, packaging duration and emergency response procedures should be considered before the shipment leaves its origin.
The objective is not simply to react when something goes wrong, but to be prepared for disruption before it occurs.
A More Connected Supply Chain
As cell and gene therapies continue to evolve, logistics will increasingly depend on the integration of specialist packaging, monitoring technology, regulatory expertise and global transport networks.
The future of advanced therapy logistics will be defined by visibility, traceability and precision.
At Medair, we understand that these shipments represent more than cargo. They can form part of a critical treatment pathway where timing and product integrity matter at every stage.
Every degree matters. Every moment counts.
Talk to a Medair specialist about cell & gene therapy logistics
